Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects

Nephrology Dialysis Transplantation

Volumn 28, Issue 4, 2013, Pages 964-971

  Marra, Maurizio ^a   Marchegiani, Francesca ^a   Ceriello, Antonio ^b   Sirolla, Cristina ^a   Boemi, Massimo ^a   Franceschi, Claudio ^c   Spazzafumo, Liana ^a   Testa, Ivano ^d   Bonfigli, Anna Rita ^a   Cucchi, Michela ^a   Testa, Roberto ^a  

^a INRCA   (Italy)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

ADMA; chronic renal impairment; dimethylarginine dimethylamino hydrolase polymorphism; type 2 diabetes mellitus

Indexed keywords

DIMETHYLARGININASE; DNA; N(G),N(G) DIMETHYLARGININE;

ADULT; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DDAH2 GENE; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; AMIDOHYDROLASES; ARGININE; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NITRIC OXIDE; POLYMORPHISM, GENETIC; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84875980119     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs516     Document Type: Article

References (28)

1. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-1992 (Pubitemid 39031337)
2. Cooke JP. Asymmetrical dimethylarginine: the Uber Marker? Circulation 2004; 109: 1813-1819
3. Kielstein JT, Impraim B, Simmel S et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177 (Pubitemid 38114135)
4. Matsuguma K, Ueda S, Yamagishi S et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176-2183 (Pubitemid 44141907)
5. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609-1616 (Pubitemid 35478130)
6. Fliser D, Kronenberg F, Kielstein JT et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461 (Pubitemid 41725064)
7. Ravani P, Tripepi G, Malberti F et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455 (Pubitemid 41725063)
8. Kielstein JT, Böger RH, Bode-Böger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176 (Pubitemid 34042024)
9. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117 (Pubitemid 34094901)
10. MacAllister RJ, Parry H, Kimoto M et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540 (Pubitemid 27019525)
11. Böger RH, Sullivan LM, Schwedhelm E et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-1600
12. Lin KY, Ito A, Asagami T et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992 (Pubitemid 34925335)
13. Tojo A, Welch WJ, Bremer V et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601 (Pubitemid 28032063)
14. Matsumoto Y, Ueda S, Yamagishi S et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18: 1525-1533 (Pubitemid 46717519)
15. Abhary S, Burdon KP, Kuot A et al. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 2010; 5: e9462
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30: S42-S47
17. Lattanzio F, Corsonello A, Abbatecola AM et al. Relationship between renal function and physical performance in elderly hospitalized patients. Rejuvenation Res 2012 [Epub ahead of print]
18. Marra M, Bonfigli AR, Testa R et al. High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Anal Biochem 2003; 318: 13-17 (Pubitemid 36627477)
19. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
20. Schwedhelm E, Böger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011; 7: 275-285
21. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4: 33-40 (Pubitemid 38234493)
22. Jones LC, Tran CT, Leiper JM et al. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003; 310: 836-843 (Pubitemid 37188698)
23. Zoccali C, Maas R, Cutrupi S et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 2007; 22: 801-806 (Pubitemid 46351688)
24. Datta PK, Sharma M, Duann P et al. Effect of nitric oxide synthase inhibition on proteinuria in glomerular immune injury. Exp Biol Med 2006; 231: 576-584
25. Sharma M, McCarthy ET, Savin VJ et al. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int 2005; 68: 2735-2744 (Pubitemid 43251018)
26. Giner V, Tormos C, Chaves FJ et al. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004; 255: 588-594 (Pubitemid 38534872)
27. Ozdemir G, Ozden M, Maral H et al. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. Ann Clin Biochem 2005; 42(Pt 2): 99-104 (Pubitemid 40516139)
28. Yasuda S, Miyazaki S, Kanda M et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006; 27: 1159-1165